
Sign up to save your podcasts
Or


In this week's episode we’ll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.
Featured Articles:
By American Society of Hematology4.1
4949 ratings
In this week's episode we’ll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.
Featured Articles:

11,155 Listeners

139 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,156 Listeners

2 Listeners

363 Listeners

372 Listeners

1 Listeners

48 Listeners

189 Listeners

30 Listeners

4 Listeners